Short answer
Kodiak Sciences Inc. (KOD) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$58M
- −1.2% YoY
- EPS (diluted)
- −$0.94
- +13.8% YoY
Source: XBRL data from the Kodiak Sciences Inc. (KOD) Q1 2026 10-Q on SEC EDGAR. USD.
Kodiak Sciences Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, precommercial biotechnology company
- R&D expenses $48.5M vs $43.6M YoY, up $4.9M
- Operating loss $59.8M vs $59.1M; operating margin not disclosed
- KSI-501 R&D highest at $9.9M; tarcocimab lowest at $9.9M, down $4.3M YoY
- Cash and equivalents $169.5M at March 31, 2026; funding expected into 2027 with additional capital planned
Risk Factors
- No material-change statement provided; section retains clinical-stage risk, with no approved products or revenue
- Regulatory risk: FDA may reject DAYBREAK’s AI-based dosing approach or require separate review
- Clinical risk: prior GLEAM and GLIMMER trials missed primary efficacy endpoints, partly associated with increased cataracts
- Operational risk: ongoing PEAK and PINNACLE enrollment for KSI-101 exposes timelines to recruitment delays
- Commercial risk: competitors could develop therapeutics or platforms rendering ABC Platform candidates obsolete
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Kodiak Sciences Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.